Phaseline

Companies › Shanghai HEP Pharmaceutical

Shanghai HEP Pharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Infectious disease.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Hepalatide (L47)
Bile acid transporter inhibitor
SLC10A1Phase 2Hepatitis D–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06505928Hepalatide (L47)Phase 2Hepatitis DInfectious diseaseMay 2026

Targets

SLC10A1 (1)

Companies with the same targets

–

Companies built like this

Osivax Artcline BiomX Curevo Green Cross

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.